Research Papers:
MiR-497 decreases cisplatin resistance in ovarian cancer cells by targeting mTOR/P70S6K1
Metrics: PDF 2287 views | HTML 3280 views | ?
Abstract
Shaohua Xu1,*, Guang-Bo Fu2,*, Zhen Tao4, Jun OuYang5, Fanfei Kong1, Bing-Hua Jiang6,7, Xiaoping Wan1 and Ke Chen3
1 Department of Obstetrics and Gynecology, Shanghai First Matenity and Infant Hospital, Tongji University School of Medicine, Shanghai, China
2 Department of Urology and Pathology, Huai’an First People’s Hospital, Nanjing Medical University, Huai’an, China
3 Cancer Center, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China
4 Department of Science and Technology, Radiation Oncology Department, Tianjin Medical University Cancer Hospital and Institute, Tianjin, China
5 Changzhou Maternal and Child Health Hospital Affiliated to Nanjing Medical University, Changzhou, China
6 State Key lab of Reproductive Medicine, Cancer Center, Nanjing Medical University, China
7 Department of Pathology, Anatomy and Cell Biology, Thomas Jefferson University, Philadelphia, PA, USA
* These authors have contributed equally to this work
Correspondence to:
Xiaoping Wan, email:
Ke Chen, email:
Keywords: miR-497, mTOR, p70S6K1, cisplatin resistance, ovarian cancer
Received: January 13, 2015 Accepted: June 25, 2015 Published: July 03, 2015
Abstract
The mechanism of cisplatin resistance in ovarian cancer is not clearly understood. In the present investigation, we found that the expression levels of miR-497 were reduced in chemotherapy-resistant ovarian cancer cells and tumor tissues due to hypermethylation of miR-497 promoter. Low miR-497 expression levels were associated with chemo-resistant phonotype of ovarian cancer. By analyzing the expression levels of miR-497, mTOR and p70S6K1 in a clinical gene-expression array dataset, we found that mTOR and p70S6K1, two proteins correlated to chemotherapy-resistance in multiple types of human cancers, were inversely correlated with miR-497 levels in ovarian cancer tissues. By using an orthotopic ovarian tumor model and a Tet-On inducible miR-497 expression system, our results demonstrated that overexpression of miR-497 sensitizes the resistant ovarian tumor to cisplatin treatment. Therefore, we suggest that miR-497 might be used as a therapeutic supplement to increase ovarian cancer treatment response to cisplatin.
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 4762